FDA
-
-
-
-
-
-
-
Cartesian advances Descartes-08 trials across multiple autoimmune conditions
-
-
-
-
-
-
-
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
-
-
-
-
-
-
-
Cartesian Therapeutics' (RNAC) Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
-
-
-
-
-
-
-
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
-
-
-
-
-
-
-
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
-
-
-
-
-
-
-
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Reports Positive Topline Results from Phase 2b Trial of Descartes-08
-
323,582 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

